ClinicalTrials.gg
RecruitingNCT06696638Updated Jan 6, 2025

Physiological Effects of Lung Impedance Tomography-Guided and Plat Pressure-Guided Phigh During APRV in Patients With ARDS

An interventional study of EIT-guided Phigh settings during APRV in ARDS: Acute Respiratory Distress Syndrome, sponsored by XiaoJing Zou,MD. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by XiaoJing Zou,MD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
24th of 31
26 · median 60
Started
2025
with 4 others
No phase
20 of 59
6 open now
Primary completion
2026-12
later than 8 of 19 live
Registered
37th of 59
by date

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 24th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 20 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 37th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

This study aims to investigate the effects of EIT-guided and Pplat-guided Phigh settings on regional ventilation and perfusion in ARDS patients during APRV, while also examining the impact of different Phigh settings on gas exchange, respiratory mechanics, and hemodynamics.

03

Conditions studied

  • ARDS: Acute Respiratory Distress Syndrome

Browse trials for

Keywords

  • ARDS
  • APRV
  • EIT
  • Phigh
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with ARDS according to the 2023 global new definition of ARDS.
  • Age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  • Severe , severe asthma, pulmonary bullae, pneumothorax, subcutaneous emphysema, mediastinal emphysema, etc. · for EIT, such as chest wound dressing, pacemaker implantation, defibrillator use, etc.
  • Pulmonary interstitial disease.
  • Uncorrected shock of various types.
  • Intracranial hypertension.
  • Pregnant and postpartum women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Intervention group

    EIT-guided Phigh settings during APRV

    Device: EIT-guided Phigh settings during APRV

  • No intervention
    Control group

    Pplat-guided Phigh settings during APRV

Interventions

  • DeviceEIT-guided Phigh settings during APRV

    The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.

06

What researchers measure

Primary outcomes

  1. The effects of Phigh guided by different methods on regional lung ventilation assessed by EIT

    Time frame: 1 Hour Post-Intervention

Secondary outcomes

  1. Global inhomogeneity assessed by electrical impedance tomography

    Time frame: 1 Hour Post-Intervention

  2. Center of ventilation assessed by electrical impedance tomography

    Time frame: 1 Hour Post-Intervention

  3. ventilation/perfusion matching assessed by EIT

    Time frame: 1 Hour Post-Intervention

  4. Respiratory system compliance

    Tidal volume divided by plateau pressure

    Time frame: 1 Hour Post-Intervention

  5. mean arterial pressure

    Time frame: 1 Hour Post-Intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

Of 51 non-industry interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 23 months is above that.

Counting every sponsor, half of 52 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 20, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06696638
Lead sponsor
XiaoJing Zou,MD
Responsible party
XiaoJing Zou,MD (Clinical Professor, Wuhan Union Hospital, China) — Sponsor-investigator
First posted
Nov 20, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 6, 2025

Study contacts

jing Xiao Zou
Contact
249126734@qq.com
+862785351606

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion